Randomized, Placebo-Controlled Study for Immunosuppressive Treatment of Inflammatory Dilated Cardiomyopathy: Two-Year Follow-Up Results

Background—Previous studies have shown disappointing results for immunosuppressive treatment in patients with dilated cardiomyopathy. Therefore, we studied the effectiveness of such therapy in patients with HLA upregulation on biopsy. Methods and Results—Of 202 patients with dilated cardiomyopathy, 84 patients with increased HLA expression were randomized to receive either immunosuppression or placebo for 3 months; they were then followed for 2 years. After 2 years, there were no significant differences in the primary end point (a composite of death, heart transplantation, and hospital readmission) between the 2 study groups (22.8% for the immunosuppression group and 20.5% for the placebo). The secondary efficacy end point included changes in ejection fraction, end-diastolic diameter, end-diastolic volume, end-systolic volume and NYHA class; left ventricular ejection fraction increased significantly in the immunosuppression group compared with the placebo group (95% CI, 4.20 to 13.12;P <0.001) after 3 months of follow-up. The early favorable effects of immunosuppressive therapy on left ventricular volume, left ventricular diastolic dimension, and New York Heart Association class were also present. This improvement was maintained in the immunosuppression group at 2 years (ejection fraction: 95% CI, 6.94 to 19.04;P <0.001). In addition, on the basis of the protocol-specified definition of improvement, 71.8% patients in the immunosuppression group versus 20.9% patients in the placebo group met the criteria of improvement after 3 months (P <0.001). At the end of the follow-up period, 71.4% patients from the immunosuppression group versus 30.8% patients from the placebo group were improved (P =0.001). Conclusions—These data demonstrate a long-term benefit of immunosuppressive therapy in patients with dilated cardiomyopathy and HLA upregulation on biopsy specimens. Thus, restoration of immunosuppressive therapy for such patients should be considered.

[1]  B. McManus,et al.  Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. , 1989, Journal of the American College of Cardiology.

[2]  B. McManus,et al.  A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. , 1995, The New England journal of medicine.

[3]  K. Sell,et al.  Abnormal expression of histocompatibility and mitochondrial antigens by cardiac tissue from patients with myocarditis and dilated cardiomyopathy. , 1991, The American journal of pathology.

[4]  K. Bailey,et al.  Long-term outcome of patients with biopsy-proved myocarditis: comparison with idiopathic dilated cardiomyopathy. , 1995, Journal of the American College of Cardiology.

[5]  J E Parrillo,et al.  A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. , 1989, The New England journal of medicine.

[6]  A. Herskowitz,et al.  Autoimmunity in myocarditis: models and mechanisms. , 1993, Clinical immunology and immunopathology.

[7]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[8]  C. Hengstenberg,et al.  Immunosuppressive treatment in autoreactive myocarditis--results from a controlled trial. , 1994, Postgraduate medical journal.

[9]  C. Badorff,et al.  Cell-mediated cytotoxicity in hearts with dilated cardiomyopathy: correlation with interstitial fibrosis and foci of activated T lymphocytes. , 1997, Journal of the American College of Cardiology.

[10]  I. Palacios,et al.  "Borderline" myocarditis: an indication for repeat endomyocardial biopsy. , 1990, Journal of the American College of Cardiology.

[11]  M. Sole,et al.  Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. , 1993, Journal of the American College of Cardiology.

[12]  G. Wallukat,et al.  Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. , 1994, Circulation.

[13]  R. D. Latham,et al.  Recently diagnosed idiopathic dilated cardiomyopathy: incidence of myocarditis and efficacy of prednisone therapy. , 1989, American heart journal.

[14]  E. Hammond,et al.  Predictive value of immunofluorescence and electron microscopic evaluation of endomyocardial biopsies in the diagnosis and prognosis of myocarditis and idiopathic dilated cardiomyopathy. , 1987, American heart journal.

[15]  E. Bonifacio,et al.  Novel organ-specific circulating cardiac autoantibodies in dilated cardiomyopathy. , 1990, Journal of the American College of Cardiology.

[16]  S. Albelda,et al.  Differential expression of the cell adhesion molecules ICAM-1, VCAM-1, and E-selectin in normal and posttransplantation myocardium. Cell adhesion molecule expression in human cardiac allografts. , 1994, Circulation.

[17]  M. Zembala,et al.  Immunohistological diagnosis of myocarditis. Potential role of sarcolemmal induction of the MHC and ICAM-1 in the detection of autoimmune mediated myocyte injury. , 1998, European heart journal.

[18]  R. Shabetai,et al.  Endomyocardial biopsy in patients with unexplained congestive heart failure. , 1988, Annals of internal medicine.

[19]  H. Aretz.  Myocarditis: the Dallas criteria. , 1987, Human pathology.

[20]  S. Coughlin,et al.  Idiopathic dilated cardiomyopathy. , 1994, The New England journal of medicine.

[21]  K. Sell,et al.  Induction of major histocompatibility complex antigens within the myocardium of patients with active myocarditis: a nonhistologic marker of myocarditis. , 1990, Journal of the American College of Cardiology.

[22]  B. Gersh,et al.  The Clinical Course of Idiopathic Dilated Cardiomyopathy , 1992, Annals of Internal Medicine.

[23]  C. Kawai,et al.  From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. , 1999, Circulation.

[24]  W. Barry.  Mechanisms of immune-mediated myocyte injury. , 1994, Circulation.

[25]  M. Yacoub,et al.  Isolation, culture, and characterisation of MHC class II-positive microvascular endothelial cells from the human heart. , 1996, Microvascular research.

[26]  P. Poole‐Wilson.  Idiopathic dilated cardiomyopathy. , 1990, BMJ.

[27]  J. O’Connell.  The role of myocarditis in end-stage dilated cardiomyopathy. , 1987, Texas Heart Institute journal.

[28]  H. Schultheiss,et al.  Treatment of chronic myocarditis with corticosteroids. , 1995, European heart journal.

[29]  H. Schultheiss,et al.  Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. , 1999, Circulation.

[30]  E. Jones,et al.  Expression of major histocompatibility complex antigens and adhesion molecules in hearts of patients with chronic Chagas' disease. , 1993, The American journal of tropical medicine and hygiene.